Macomics has expanded its advisory team with the appointment of Prof. Michele De Palma and Dr Jackie Doody, internationally renowned experts in the fields of immuno-oncology.
Prof. Michele De Palma, Swiss Federal Institute of Technology in Lausanne (EPFL), leads research into tumor microenvironment including tumour associated macrophages, tumour angiogenesis and immunotherapies. His previous work has led to the first-in-kind clinical trials of engineered monocytes in patients with brain and haematological cancers.
Dr Jacqueline Doody has over 30 years of industry experience and is ex-VP of Immuno-oncology at F-star working on bispecific antibody therapies targeting T cells. Dr Doody headed the Immunology department at ImClone taking antibody programs to the clinical stage, including the macrophage program on CSF-1R.
They join Dr John Haurum as advisors. Dr Haurum has over 20 years experience in the international biotech industry. Previously John was Chief Executive Officer of F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies, with multiple strategic collaborations with AbbVie, Merck KGaA, Denali and Boehringer Ingelheim.